Status | Study |
Completed |
Study Name: MESA Treatment for NK/T Cell Lymphoma Condition: Lymphoma, Extranodal NK-T-Cell Date: 2013-08-16 Interventions: Drug: MESA chemotherapy Methot |
Recruiting |
Study Name: Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma Condition: Extranodal NK/T-cell Lymphoma, Nasal Type Date: 2013-08-03 Interventions: Biological: Avastin Avastin 7. |
Completed |
Study Name: Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma Condition: Extranodal NK/T-cell Lymphoma, Nasal Type Date: 2012-08-13 Interventions: Drug: Radiotherapy followed by chemotherapy Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: |
Terminated |
Study Name: Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma Condition: Extranodal NK/T-cell Lymphoma, Nasal Type Date: 2012-08-13 Interventions: Radiation: Radiotherapy alone |
Completed |
Study Name: Gemcitabine in NK/T Cell Lymphoma Condition: NK/T Cell Lymphoma Date: 2012-08-06 |
Recruiting |
Study Name: Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ Condition: Nasal and Nasal-type NK/T-cell Lymphoma Date: 2011-11-29 Interventions: Drug: DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase) |
Recruiting |
Study Name: Treatment of Natural Killer/T Cell Lymphoma-I/II Condition: Nasal and Nasal-type NK/T-cell Lymphoma Date: 2011-11-25 Interventions: Other: DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase) |
Completed |
Study Name: Retrospective Analysis of Skin/Soft Tissue Primary NK/T Cell Lymphoma Condition: Extranodal NK/T Cell Lymphoma Date: 2011-04-21 |
Completed |
Study Name: Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma Condition: Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type Date: 2010-09-08 Interventions: Radiation: CCRT+MIDLE chemotherapy Patients are planned to be treated with CCRT plus MIDLE chemotherapy |
Active, not recruiting |
Study Name: Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy in NK/T-cell Lymphoma Condition: Stage I/II Extranodal NK/T-cell Lymphoma Date: 2009-11-02 Interventions: Other: concomitant chemo-radiotherapy followed by VIDL chemotherapy with risk-based application of autologous stem cell transplantation |